$SRRK

Gilman Michael sold $137K of SRRK

Gilman Michael sold 2,544 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.54–$54.81, $0.14M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gilman Michael
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new company fundamentals such as guidance, trial results, contracts, or regulatory actions.

02

Market read

Primarily a sentiment/positioning datapoint for SRRK, with limited expected impact given the 10b5-1 structure.

03

What to watch

The article provides sale size and weighted prices but no context on total holdings, future planned sales, or whether other insiders have concurrent activity.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported as an open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Form 4 shows director Gilman Michael sold 2,544 SRRK shares in open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal, though it can add slight overhang sentiment if traders focus on insider selling.

Evidence & confidence

The transaction is disclosed via SEC Form 4 and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity and taxes rather than signal bearish views.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider sale disclosure.

  • Gilman Michael

    Director who sold SRRK shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

$NVOMed

Weight-loss drug developers line up to tap lucrative market

The weight-loss drug market is growing rapidly, with analysts projecting $100B in annual sales in the next decade. Novo Nordisk and Eli Lilly lead the sector, but other companies like Pfizer, Viking Therapeutics, and AstraZeneca are developing new treatments. Key drugs include Novo's amycretin and CagriSema, Pfizer's PF-3944, and Lilly's retatrutide, with varying degrees of success in clinical trials.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.